Please login to the form below

Not currently logged in
Email:
Password:

mutiple myeloma

This page shows the latest mutiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Mixed cancer news from NICE

Mixed cancer news from NICE

Mixed cancer news from NICE. Agency backs Janssen’ s myeloma drug but denies Bayer’ s Xofigo in prostate cancer. ... The cost-effectiveness agency issued draft guidance giving the green light to Janssen's Velcade in the treatment of certain patients

Latest news

  • NICE denies early use of Janssen’s Velcade NICE denies early use of Janssen’s Velcade

    Janssen's Velcade is not a cost-effective use of NHS resources for the early treatment of multiple myeloma, according to new draft guidance from England's health guidance body. ... The drug is already recommended by NICE for use in combination with an

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics